| Randall L Woodford, MD | |
|
5301 Virginia Way, 300, Brentwood, TN 37027-7541 | |
| (615) 221-4474 | |
| (615) 234-3774 |
| Full Name | Randall L Woodford |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 5301 Virginia Way, Brentwood, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023223898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 0101246889 (Virginia) | Primary |
| Entity Name | Gastroenterology Consultants Of |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417993833 PECOS PAC ID: 1951362607 Enrollment ID: O20041026000086 |
News Archive
Volume V, Issue 2 of the online journal Global Health Governance is now available online. Among other articles, the issue features a piece examining the sustainability of sub-regional disease surveillance networks, a piece examining the impact of regional health meetings in the Pacific on health governance, and a commentary on investing in strengthening health systems.
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry of psoriasis and COVID-19 patients, led by Guy's and St Thomas' clinicians, over 90% survive.
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.
› Verified 7 days ago
| Entity Name | Pathology Consultants Of Central Va, Inc |
|---|---|
| Entity Type | Part B Supplier - Independent Clinical Laboratory |
| Entity Identifiers | NPI Number: 1598863821 PECOS PAC ID: 3971669292 Enrollment ID: O20090311000269 |
News Archive
Volume V, Issue 2 of the online journal Global Health Governance is now available online. Among other articles, the issue features a piece examining the sustainability of sub-regional disease surveillance networks, a piece examining the impact of regional health meetings in the Pacific on health governance, and a commentary on investing in strengthening health systems.
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry of psoriasis and COVID-19 patients, led by Guy's and St Thomas' clinicians, over 90% survive.
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.
› Verified 7 days ago
| Entity Name | Associated Pathologists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003863580 PECOS PAC ID: 0648167544 Enrollment ID: O20150203001627 |
News Archive
Volume V, Issue 2 of the online journal Global Health Governance is now available online. Among other articles, the issue features a piece examining the sustainability of sub-regional disease surveillance networks, a piece examining the impact of regional health meetings in the Pacific on health governance, and a commentary on investing in strengthening health systems.
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry of psoriasis and COVID-19 patients, led by Guy's and St Thomas' clinicians, over 90% survive.
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Randall L Woodford, MD 5301 Virginia Way, 300, Brentwood, TN 37027-7541 Ph: (615) 221-4474 | Randall L Woodford, MD 5301 Virginia Way, 300, Brentwood, TN 37027-7541 Ph: (615) 221-4474 |
News Archive
Volume V, Issue 2 of the online journal Global Health Governance is now available online. Among other articles, the issue features a piece examining the sustainability of sub-regional disease surveillance networks, a piece examining the impact of regional health meetings in the Pacific on health governance, and a commentary on investing in strengthening health systems.
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry of psoriasis and COVID-19 patients, led by Guy's and St Thomas' clinicians, over 90% survive.
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.
› Verified 7 days ago
Kathy Bruner, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5301 Virginia Way, Suite 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Kenneth S Piech, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 5301 Virginia Way, Ste 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Roy W. Kirchberg Jr., M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Virginia Way, Ste 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Dr. Lori D Emerson, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Virginia Way, Suite 300, Brentwood, TN 37027 Phone: 615-695-4977 | |
Ben W Davis, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Virginia Way Ste 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Dr. Soheila Yadrandji, MD Pathology Medicare: Medicare Enrolled Practice Location: 5301 Virginia Way, Suite 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 |